`571-272-7822
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Paper 56
`Entered: October 25, 2016
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`_______________
`
`PATENT TRIAL AND APPEAL BOARD
`_______________
`
`COALITION FOR AFFORDABLE DRUGS V LLC;
`HAYMAN CREDES MASTER FUND, L.P.;
`HAYMAN ORANGE FUND SPC – PORTFOLIO A;
`HAYMAN CAPITAL MASTER FUND, L.P.;
`HAYMAN CAPITAL MANAGEMENT, L.P.;
`HAYMAN OFFSHORE INVESTMENTS, LLC;
`NXN PARTNERS, LLC;
`IP NAVIGATION GROUP, LLC;
`KYLE BASS, and ERICH SPANGENBERG,
`Petitioners,
`
`
`
`v.
`
`BIOGEN MA INC.,
`Patent Owner,
`__________
`
`Case IPR2015-01993
`Patent 8,399,514 B2
`__________
`
`BIOGEN MA INC.,
`Junior Party,
`Patent 8,399,514 B2,
`
`v.
`
`FORWARD PHARMA A/S
`Senior Party,
`Application 11/576,871.
`
`
`
`
`
`
`
`Patent Interference No. 106,023
`Technology Center 1600
`
`
`Order
`Oral Arguments
`
`
`
`Before RICHARD E. SCHAFER, Administrative Patent Judge.
`
`
`
`Oral arguments in the above proceedings are set to begin at 9:30 a.m.,
`
`November 30, 2016, in Hearing Room B, 9th Floor, Madison Building East,
`
`600 Dulany Street, Alexandria, Virginia,1
`
`
`
`The arguments in IPR 2014-01993 will be heard first. Each party will have
`
`20 minutes. Petitioner will present its argument first. Each party may save a
`
`portion of its time for rebuttal. The Board will then take a short recess to allow the
`
`interference parties to set up for their arguments in Interference 106,023. Each
`
`party in interference 106,023 will have 30 minutes and may save a portion of that
`
`time for rebuttal. The junior party will present its arguments first.
`
`
`
`The hearing will be open to the public. In-person attendance will be
`
`accommodated on a first-come, first-served basis.
`
`
`
`The Board will provide a court reporter for the hearing and the reporter’s
`
`transcript will constitute the official record of the hearing. Any demonstrative
`
`exhibits must be served seven business days before the hearing. The
`
`demonstratives shall not be filed with the Board. A hard copy of the
`
`demonstratives shall be provided to each APJ and to the court reported at the
`
`beginning of the argument. Neither the oral argument nor demonstrative exhibits
`
`constitute evidence (other than possible admissions). The demonstratives may not
`
`
`1 Oral argument in IPR2015-01993 is tentative pending the submission of a request
`for oral argument by Coalition and Biogen as set in the Scheduling Order of
`April 19, 2016 (Paper 34).
`
`
`
`2
`
`
`
`introduce new evidence or argument. Demonstrative exhibits must cite to the
`
`location of the evidence in the record.
`
`Questions regarding specific audio-visual equipment should be directed to
`
`the Board at (571) 272-9797. Requests for audio-visual equipment are to be made
`
`five (5) days in advance of the hearing date. The request is to be sent to
`
`Trials@uspto.gov. If the request is not timely received, the equipment may not be
`
`available on the day of the hearing. The parties are reminded that the presenter
`
`must identify clearly and specifically each demonstrative exhibit (e.g., by slide or
`
`screen number) referenced during the hearing to ensure the clarity and accuracy of
`
`the reporter’s transcript.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`3
`
`
`
`Counsel for Coalition for Affordable Drugs:
`
`James T. Carmichael
`Carol A. Spiegel
`Carmichael IP, PLLC
`jim@carmichaelip.com
`carol@carmichaelip.com
`
`Counsel for Biogen MA Inc.:
`
`Michael Flibbert
`Maureen D. Queler
`Erin M. Sommers
`Michele C. Bosch
`Barbara C. McCurdy
`Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
`Michael.flibbert@finnegan.com
`Maureen.queler@finnegan.com
`Erin.sommers@finnegan.com
`Michele.bosch@finnegan.com
`Barbara.mccurdy@finnegan.com
`
`
`
`Counsel for Forward Pharma A/S:
`
`Anthony M. Zupcic
`Daniel S. Glueck
`Fitzpatrick, Cella, Harper & Scinto
`Azupcic@fchs.com
`Dglueck@fchs.com
`
`Brian V. Slater
`Kramer Levin Naftalis & Frankel, LLP
`BSlater@kramerlevin.com
`
`
`
`4
`
`